Aviva reported H1 2026 operating profit of £1,326 million on Thursday - up 24% year on year and the strongest first-half result the group has recorded under its current structure. For UK brokers, the more useful read is not the headline but the segment data underneath it, which tells a clear story about where Aviva is growing, where it is holding the line, and what that means for renewals in the second half.
The group numbers: operating profit up 24% to £1,326 million, operating earnings per share up 10% to 31.8p, IFRS return on equity of 20.3%, and cash remittances up 47% to £1,498 million. The interim dividend has been raised 7% to 14.0 pence per share. The Solvency II shareholder cover ratio was 176% at June 30 - comfortably above the working range, and expected to recover to the high-180s by year-end as remaining Direct Line capital synergies of more than £350 million receive regulatory approval.
Aviva's long-term growth areas, specifically named by Group CEO Amanda Blanc in the results, are Wealth, UK and Canada General Insurance, Global Corporate and Specialty, and Health and Protection. Those four areas are the direction of travel. Everything else tells brokers where Aviva is managing, not building.
The detail UK commercial brokers need is in a single line of the results: UK commercial lines premiums were 4% lower at £1,927 million, with Aviva citing "deliberate underwriting discipline to manage profitability in softer market conditions, prioritising profitable growth over volume."
The commercial lines undiscounted combined ratio of 93.7% - up 0.2 percentage points from H1 2025's 93.5% - confirms this is a carrier holding its standards rather than defending market share. Aviva has explicitly flagged that it expects the softer rating environment to persist for the remainder of 2026 and will continue to prioritise underwriting discipline. For brokers placing commercial risks with Aviva, that is the clearest possible signal: Aviva will not chase business at inadequate terms. Submissions need to demonstrate underwriting quality, not just a competitive premium.
The exception is Global Corporate and Specialty. Strong April renewals in GCS partially offset the softer broader commercial environment, and Blanc explicitly named GCS as a long-term growth platform. Aviva operates GCS through integrated company and Lloyd's platforms. Brokers with large corporate, specialty, or multinational risks should note that this is the corner of the commercial book where Aviva is actively building, not managing for stability.
UK personal lines premiums grew 98% to £3,679 million - but this is almost entirely a function of the Direct Line acquisition completing on July 1, 2025 and therefore not being in the H1 2025 comparator. The more meaningful indicator for personal lines brokers is the combined ratio: personal lines came in at 93.1%, improved by 0.8 percentage points year on year. Motor policies on price comparison websites grew 7% since the acquisition, with TNPS above 50 and improved motor claims satisfaction.
The Direct Line integration is moving quickly. All Direct Line employees have been transferred to Aviva. Nearly £5 billion of assets have been transferred to Aviva Investors. £100 million of run-rate cost synergies have been delivered toward the £225 million ambition, with approximately £130 million of cumulative run-rate cost synergies expected by year-end. For brokers distributing Direct Line products through intermediated channels, the signal is continuity: Aviva has maintained customer service standards throughout the integration, which de-risks the transition for clients already mid-policy.
Aviva won 232 new Workplace schemes in H1 alone, with net flows growing 36% to £5.1 billion. The initial transfers from the Mercer Master Trust added £1.5 billion, with further flows expected by year-end. The Adviser Platform added 10% more customers in the last year to 460,000, and Wealth operating profit grew 34% to £102 million - the fastest-growing segment in IWR.
For employee benefits brokers and financial advisers distributing through Aviva's platform, this is the context for what it means to bring a new scheme mandate: Aviva is in active competition for new business at scale, which gives brokers both leverage and responsibility in the relationship. A Workplace provider winning 232 schemes in six months is one investing heavily in the client acquisition experience - and one whose competitive servicing proposition is being tested and refined at volume. Brokers advising employers on provider selection should be asking Aviva to demonstrate that proposition in detail, because the pipeline and investment are clearly there.
Health in-force premiums grew 5%, driven by pricing ahead of inflation. But new business sales fell 33% to £51 million, as Aviva maintained rate discipline in the consumer and SME channels where pricing competition has intensified. Aviva has lowered its full-year Health operating profit guidance to approximately £90 million, citing slowing market growth in those channels.
For corporate health brokers, this is a clear positioning signal: Aviva is not competing on price in consumer and SME Health. Its focus is on the large corporate segment and managing margin. Brokers placing SME health business should expect Aviva to hold its terms rather than move on price to win.
Aviva is accelerating AI deployment across claims, underwriting, and Wealth. Specific developments flagged in the results include faster medical underwriting review times, automated quality assurance in Wealth, a virtual assistant launching later this year, and an AI-enabled claims agent. For brokers, the claims agent is the most operationally significant: an AI-driven first response on claims handling has direct implications for speed of settlement and the experience their clients receive post-loss.
